Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,764 | $11,476 | $22,100 | $7,394 |
| % Growth | -75.9% | -48.1% | 198.9% | – |
| Cost of Goods Sold | $74,094 | $2,084 | $0 | $0 |
| Gross Profit | -$71,330 | $9,392 | $22,100 | $7,394 |
| % Margin | -2,580.7% | 81.8% | 100% | 100% |
| R&D Expenses | $74,094 | $78,388 | $80,255 | $71,817 |
| G&A Expenses | $17,336 | $17,645 | $16,271 | $16,332 |
| SG&A Expenses | $17,336 | $17,645 | $16,271 | $16,332 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$70,239 | -$2,084 | $0 | $0 |
| Operating Expenses | $21,191 | $93,949 | $96,526 | $88,149 |
| Operating Income | -$92,521 | -$84,557 | -$74,426 | -$80,755 |
| % Margin | -3,347.4% | -736.8% | -336.8% | -1,092.2% |
| Other Income/Exp. Net | $10,346 | $7,943 | $8,845 | $10,003 |
| Pre-Tax Income | -$82,175 | -$76,614 | -$65,581 | -$70,752 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$82,175 | -$76,614 | -$65,581 | -$70,752 |
| % Margin | -2,973% | -667.6% | -296.7% | -956.9% |
| EPS | -0.94 | -0.95 | -0.82 | -0.88 |
| % Growth | 1.1% | -15.9% | 6.8% | – |
| EPS Diluted | -0.94 | -0.95 | -0.82 | -0.88 |
| Weighted Avg Shares Out | 87,300 | 80,449 | 80,147 | 79,987 |
| Weighted Avg Shares Out Dil | 87,300 | 80,449 | 80,147 | 79,987 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,346 | $8,051 | $8,917 | $10,062 |
| Interest Expense | $0 | $108 | $72 | $59 |
| Depreciation & Amortization | $2,849 | $2,084 | $2,048 | $1,987 |
| EBITDA | -$79,326 | -$74,422 | -$63,461 | -$68,706 |
| % Margin | -2,870% | -648.5% | -287.2% | -929.2% |